To evaluate the clinical features of intravitreal bevacizumab injection in patients with macular hemorrhage (submacular or subinternal limiting membrane hemorrhage) secondary to a retinal arterial macroaneurysm.

We retrospectively reviewed the medical records of 17 eyes of 17 patients who underwent intravitreal bevacizumab injection with macular hemorrhage secondary to retinal arterial macroaneurysm. We evaluated the improvement of visual acuity and changes in central retinal thickness after intravitreal injections of bevacizumab. According to the final visual acuity, the characteristics of the good and poor visual prognoses groups were compared.

The mean age of patients (17 eyes) who underwent intravitreal bevacizumab treatment for macular hemorrhage secondary to retinal arterial macroaneurysm was 78.47 ± 7.84 years. The mean follow-up period was 3.99 ± 2.99 months, and the mean number of injections of bevacizumab was 2.12 ± 1.36. There were significant improvements in visual acuity and central retinal thickness, and the duration from symptom onset to treatment was shorter in patients with good visual prognoses.

Intravitreal bevacizumab injection alone was effective for improving visual acuity and decreasing central retinal thickness in patients with macular hemorrhage secondary to retinal arterial macroaneurysms.